Last edition
News about "pulmonary neuroendocrine carcinomas"
Zai Lab Secures EMA Orphan Drug Status for Zoci in Pulmonary Neuroendocrine Carcinomas
Zai Lab has received EMA Orphan Drug Designation (ODD) for zocilurtatug pelitecan (zoci) in pulmonary neuroendocrine carcinomas. The designation recognises promising clinical data suggesting potential benefits over existing therapies for patients with relapsed or refractory extensive-stage Small Cell Lung Cancer (SCLC).
Pulmonary Neuroendocrine Carcinomas | 17/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy